P2-4 Comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as 2nd-line treatment for gastric cancer
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI